DEVELOPMENT OF RESEARCH REAGENTS SPECIFIC FOR O-GLCNAC (O-GLCNAC LECTENZ)

Information

  • Research Project
  • 8744391
  • ApplicationId
    8744391
  • Core Project Number
    N44CO000000
  • Full Project Number
    261201300048C-0-0-1
  • Serial Number
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/13/2013 - 10 years ago
  • Project End Date
    9/12/2015 - 8 years ago
  • Program Officer Name
  • Budget Start Date
    -
  • Budget End Date
    -
  • Fiscal Year
    2013
  • Support Year
  • Suffix
  • Award Notice Date
    -

DEVELOPMENT OF RESEARCH REAGENTS SPECIFIC FOR O-GLCNAC (O-GLCNAC LECTENZ)

The long-term objectives of this proposal are to generate and commercialize a new class of high-specificity, high-affinity proteins called Lectenz¿, as research reagents for use in studies of disease- or cancer-related glycosylation. The specific aims are to further the development and commercialization of a new reagent, created in Phase I of this proposal, which is pan-specific for the detection of the glycan β-O-GlcNAc. By basing the design of this reagent on the biologically-relevant O-GlcNAcase enzyme, the resultant Lectenz¿ should be able to recognize the terminal O-GlcNAc glycan in its biologically-relevant context. For this reason, we refer to this Lectenz¿ as being pan-specific for O-GlcNAc. In this Phase II proposal, we will fully characterize this unique reagent and optimize its production and utility in a variety of assay formats. The ability of the pan-specific O-GlcNAc Lectenz¿ to rapidly confirm the presence of β-O-GlcNAc in proteins and tissues, without the need to turn to more-elaborate techniques, would provide a powerful tool to delineate differentially glycosylated proteins, and eventually establish correlations between β-O-GlcNAc regulation and associated disease states, such as cancer. In addition, as reported in Phase I, we have found that some clones of this reagent display variations in affinity for O-GlcNAcylated peptides, as a function of the peptide sequence. Thus, we will also continue to select for variants of the Lectenz¿ that may be used to discriminate between β-O-GlcNAcylated peptides, as a function of the peptide sequence.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    N44
  • Administering IC
    CA
  • Application Type
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    999970
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    396
  • Ed Inst. Type
  • Funding ICs
    NCI:999970\
  • Funding Mechanism
    SBIR/STTR Contracts
  • Study Section
  • Study Section Name
  • Organization Name
    GLYCOSENSORS AND DIAGNOSTICS, LLC
  • Organization Department
  • Organization DUNS
    808436633
  • Organization City
    ATHENS
  • Organization State
    GA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    306021514
  • Organization District
    UNITED STATES